FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a combination of THCV or CBD and aripiprazole or an aripiprazole metabolite specified in dehydroaripiprazole, OPC-14857, DM-1458, DM-1451, DM-1452, DM-1454 or DCPP applicable for preventing or treating psychosis or a psychotic disorder wherein THCV or CBD are administered separately, sequentially or simultaneously with aripiprazole.
EFFECT: invention provides relieving or eliminating the undesirable side effects of aripiprazole or the aripiprazole metabolite, such as anxiety, catalepsy and ptosis.
11 cl, 5 ex, 18 tbl, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL DRUG | 2019 |
|
RU2795027C2 |
| APPLICATION OF ONE OR COMBINATION OF PHYTOCANNABINOIDS FOR TREATMENT OF EPILEPSY | 2010 |
|
RU2563143C2 |
| MIXTURE CONTAINING CARBAMATE COMPOUND FOR PREVENTION, RELIEF OR TREATMENT OF SCHIZOPHRENIA | 2018 |
|
RU2772465C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTIPSYCHOTIC DRUG AND A VMAT2 INHIBITOR, AND THEIR USE | 2015 |
|
RU2757221C2 |
| METHOD OF USING 4-((1R,3S)-6-CHLORO-3-PHENYLINDANE-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND SALTS THEREOF IN TREATING SCHIZOPHRENIA | 2012 |
|
RU2613177C2 |
| THERAPEUTIC AGENTS | 2008 |
|
RU2468025C2 |
| ORGANIC COMPOUNDS | 2017 |
|
RU2733975C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING WATER-INSOLUBLE ANTIPSYCHOTIC DRUG AND SORBITAN ESTERS | 2012 |
|
RU2757859C2 |
| NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS FOR TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | 1998 |
|
RU2222330C2 |
